A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma

Inclusion Criteria

• •Age ≥ 18 years
• •Histological or cytological documentation of an advanced solid tumor
• •Subject must have metastatic or recurrent disease and have failed first-line systemic treatment, and if indicated, failed approved second-line therapy, and for whom no standard therapy options are anticipated to result in a durable remission
• •Subject must have evaluable, progressive, and measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, Version 1.1
• •Adequate bone marrow, liver, and renal function
• •Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• •For Part B (expansion) in subjects metastatic urothelial carcinoma:
• •The patient's tumor has been evaluated and prospectively identified as having FGFR 1, 2, 3, or 4 genetic alterations.